Proper Name: Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant Tradename: Cervarix Manufacturer: GlaxoSmithKline Biologicals 16 October 2009, Cervarix® was approved for use in the United States, by the FDA. To examine all available FDA documents pertaining to the approval of this HPV vaccine visit the two FDA links below. Proper Name: Human Papillomavirus […]
Cervarix
Cervarix® is manufactured by GlaxoSmithKline. For information on this bivalent HPV vaccine directly from the source, visit their website here.
PRESCRIBING INFORMATION FOR CERVARIX
INDICATIONS AND USAGE CERVARIX® is indicated for the prevention of the following diseases caused by oncogenic human papillomavirus (HPV) types 16 and 18 [see Clinical Studies (14)]: Cervical cancer Cervical intraepithelial neoplasia (CIN) grade 2 or worse and adenocarcinoma in situ, and Cervical intraepithelial neoplasia (CIN) grade 1. CERVARIX is approved for use in females […]
Human papillomavirus vaccine coverage
The Lancet, Volume 376, Issue 9738, Pages 329 – 330, 31 July 2010 Peter Bach states in his Comment1 that poorer states in the USA with higher mortality from cervical cancer have lower coverage with the human papillomavirus (HPV) vaccine than do wealthier states; however, he does not indicate the disparities in vaccination policies and […]
Patents no barrier to producing cheaper HPV vaccine
By: Wai Lang Chu, 12-Jul-2010 A new study believes vaccine manufacturers from developing countries may be able to produce a HPV vaccine at a lower cost without infringing on the numerous patents drug makers have taken out on the vaccine technology. The researcher’s findings have particular relevance with India as it shoulders almost 25 per […]
- « Previous Page
- 1
- …
- 47
- 48
- 49
- 50
- 51
- …
- 57
- Next Page »
